Physician profile
Amy Manners
NPI 1932640174
$962.50
in general payments reported to CMS, 2019-2025
13 companies · $293 in 2025
The $293 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.86 · 2020: $22.94 · 2021: $92.99 · 2022: $114 · 2023: $162 · 2024: $205 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $211.01 | 2021-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $146.72 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $133.04 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $128.16 | 2023-2025 | Daybue |
| Sanofi Pasteur INC. | $80.27 | 2021-2025 | |
| Abbvie INC. | $61.81 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.84 | 2020-2022 | |
| Glaxosmithkline, LLC. | $48.37 | 2020-2025 | Bexsero, Penmenvy |
| Corium, LLC | $25.85 | 2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $21.32 | 2024 | Flumist Quadrivalent |
| Tris Pharma INC | $19.29 | 2022 | |
| Genentech USA, INC. | $17.32 | 2021 | |
| Verrica Pharmaceuticals INC. | $13.50 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Manners listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.